Observational studyInternal and emergency medicine2026
Prognostic role of the 2MACE score in older patients with atrial fibrillation.
Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common arrhythmia in the elderly and is associated with an increased risk of cardiovascular events (CVE); indeed, a percentage of patients develop CVE during oral anticoagulation. The 2MACE score is a clinical score used to predict the risk of MACE in patients with AF, but not in elderly patients with AF. Therefore, the purpose of this work is to evaluate the possible predictive value of the 2MACE score on MACE onset, in a cohort of elderly patients with non-valvular AF and several comorbidities for long-term follow-up. 1005 elderly with non-valvular AF were enrolled (76.4 ± 6.1 years; 291 on VKAs and 714 on DOACs) and stratified according to the median value of 2MACE score. MACE (non-fatal ischemic stroke, non-fatal myocardial infarction, and cardiovascular death) and all-cause mortality occurrence were evaluated during a mean follow-up of 6.2 years. In this multicenter retrospective observational study, a 2MACE score ≥ 4 pt (taken as a dichotomous value) (HR 4.38, 95% CI 3.46-5.55; p < 0.0001) was associated with a 4.3-fold increased risk of MACE, with modest discriminatory ability (AUC: 0.65; standard error: 0.018; 95% CI, 0.62-0.69). Furthermore, the presence of MMSE score < 24 pt (HR 1.27, 95% CI 1.03-1.56, p = 0.026) was associated with a 27% increased risk of MACE. In contrast, DOACs and SGLT2-inhibitor were associated with a 55% (HR 0.45, 95% CI 0.36-0.55, p < 0.0001) and 46% (HR 0.54, 95% CI 0.41-0.71, p < 0.0001) lower risk of MACE, respectively. Elderly patients with non-valvular AF whot exhibit a 2MACE score ≥ 4 pt show a higher risk of MACE and all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.